Business Wire

BT Group Transforms its Business Approach with a Cloud Core Network from Juniper Networks to Enable New Services at Exceptional Scale and Quality Globally

Share

Juniper Networks (NYSE:JNPR), a leader in secure, AI-driven networks, today announced it is supporting BT Group’s ongoing transformation journey towards a highly scalable, automated and robust cloud core infrastructure for business and consumer customers. BT Network Cloud supports diverse network applications across broadband, fixed, mobile and other mission-critical services on a single platform, using Juniper Networks’ high-performance cloud-native solutions and professional services.

With this strategic deployment, BT Network Cloud has now scaled to accommodate multiple key network-centric applications, such as mobile voice and data, broadband authentication and IP voice calls for tens of millions of customers without extra overhead costs. An innovative global technology footprint from Juniper, including infrastructure consolidation and virtualization, along with improved hardware density and power efficiency, reduces space and power requirements in support of a more sustainable infrastructure.

BT Simplifies and Improves Service Quality with Agile Network Cloud

BT Network Cloud enables applications that underpin BT Group's U.K. consumer and business network services. Juniper’s high-performance, high-availability fabric for BT Network Cloud provides extreme robustness and high performance for BT Group’s core applications across a widely distributed user base deployed at multiple locations across the U.K. Moving from dedicated compute platforms for each application to a shared infrastructure conserves and optimizes resources leading to better resource utilization and significantly lower environmental impact.

The provider’s network cloud optimizes service quality and streamlines operational deployment and management of core applications, which enables innovation and agility in delivering new services to market such as enhanced 5G services.

5G Roll Out and Scale to Meet Digital Demand

The introduction of 5G created a unique opportunity for BT Group to transform its core network to ensure it was well-positioned to offer a dynamic range of new services to customers at unprecedented scale. BT Group chose to build a network cloud to provide a common shared platform for core applications, which operate its broadband, fixed and mobile services. BT Group has migrated tens of millions of mobile subscribers and successfully deployed all its mobile application infrastructure on its network cloud.

The goal of the multiyear journey at BT Group was to deploy a state-of-the-art container-based fixed, broadband and mobile core that will boost business agility, operational efficiency, sustainability and meet security compliance.

News Highlights:

-BT uses Juniper for open, software-defined networking (SDN), switching and firewall solutions for its network cloud. The service provider uses Juniper’s SDN platform to automate the creation and management of its OpenStack-based telco cloud. The platform provides hybrid SDN orchestration and centralized control of virtual switching, routing and security. BT is running cloud-native containerized applications and optimizing costs using OpenStack.

-Juniper QFX Series Switches provide the high-performance, high-availability fabric needed to support the BT Network Cloud which has rapidly become the largest container-based cloud infrastructure in the world, and is still growing.

-BT’s cloud-native platform is deployed at multiple locations across the U.K. to form a distributed architecture designed to scale seamlessly alongside demand and to provide services closer to the end user than with traditional, more centralized deployments.

-Juniper collaborated with BT to deliver high-performance, high-availability fabric for BT Network Cloud. BT’s data centers contain over 1,000 Juniper QFX Series Switches and 2,000 Juniper vRouters. The switches connect all mission-critical application servers to the core network. The SDN platform is deployed on the servers to provide virtualized routing capability to connect workloads across BT’s network securely.

-Juniper vSRX Virtual Firewalls protect and secure the data center traffic. vSRX provides a network address translation capability which was not possible for one of BT’s application providers to deliver in software.

-BT Group selected Juniper for its engineering excellence and ability to provide an end-to-end network solution including hardware, software and tools that can integrate reliably with the complete cloud stack.

-By leveraging Juniper’s professional services, BT has successfully completed the project on time and ensured that the challenging service level, availability and performance targets of BT’s applications are met.

Supporting Quotes:

“Telecoms services have become central to business and consumer lives and as the U.K.’s national network provider, BT Group has a particular responsibility to lead from the front to deliver the cloud-native, sustainable digital services of the future. Our work with partners such as Juniper is helping to ensure that our critical infrastructure, network and services are agile, secure and resilient for the long term. Our millions of customers can remain confident in the experience-led integrity of the everyday and exceptional digital services on which they rely.”

- Howard Watson, Chief Security and Networks Officer, BT Group

“We are delighted that Juniper’s cloud-native networking solutions and comprehensive professional services were selected as the cornerstone of the BT Network Cloud. BT can respond to the demands of the next chapter of digital transformation at scale whilst leveraging the power of the network to enable new digital services for BT’s customers, fully supported by a cloud-native architecture enabling security, automation, scale and agility.”

- Raj Yavatkar, Chief Technology Officer, Juniper Networks

Additional Resources

BT: Success Story

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Pelin Murphy
Juniper Networks
pelin@juniper.net
+44 (0) 1372 385 686

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye